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Clare Hogue
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The phrase “disease mongering” has become a prominent feature of the wider
critique of pharmaceutical marketing. Disease mongering refers to drug
companies’ involvement in informing the lay public and health professionals
about the illnesses targeted by their products. Typically, drug promotion is
claimed to intentionally distort perceptions of the seriousness or treatability of
disease or condition to sell drugs. The main concern is that drug promotion
results in excessive drug demand. “Disease mongering” is clearly aimed at
drug companies, however, the phrase reaches further and extends to us all with
its often implicit critical commentary on contemporary social life. In this report,
describe the results of an interview study with critics of pharmaceutical
marketing. We explore what disease mongering implies or assumes about the
contemporary world, particularly the doctors and consumers who inhabit it,
and why such a critique is considered necessary. The potency of the drug
promotion, the hubris of doctors and the susceptibility of consumers were the
main themes interpreted in the data. The disease mongering critique can be seen
as part of a more general critique of the processes of “biomedicalisation” and
“pharmaceuticalisation.” Keywords: Disease Mongering, Pharmaceutical
Marketing, Biomedicalisation, Pharmaceuticalisation, Grounded Theory
Introduction
Disease mongering is a pejorative term used by critics to refer to (patent rather than
generic) drug companies’ involvement in informing the public and professionals about the
illnesses targeted by their products (Applbaum 2006; Healy, 2004, 2006; Heath 2006;
Moynihan & Cassells 2005; Moynihan, Doran, & Henry 2008,). Typically, a drug company is
accused of misshaping perceptions of a disease or condition, or more pertinently, the perception
of what is “normal” and what is not and what therefore should be treated (Angell 2004;
Buckley, 2004; Caplan & Elliot 2004; Mintzes, 2006; Moynihan, 2002, Moynihan, Heath, &
Henry 2002; Triggle 2005). Critics’ main concern is that the marketing or “branding” of a
condition creates excessive drug demand – with many people using a drug that they don’t need,
won’t help them or could even make things worse (Heath, 2005, 2006; Mansfield, 2006,
Moynihan & Cassells 2005; Moynihan & Henry, 2006).
Disease mongering has been defined as “extending the boundaries of illness”
(Moynihan, Doran, & Henry, 2008) and may involve the pathologising of normal human
variation, the depiction of risk factors as diseases or the invention of a new disease (Brody &
Light, 2011; Grob, 2010; Meyer, 2003; Moynihan, Heath, & Henry, 2002; Payer, 1992). Critics
cite numerous examples disease mongering involving conditions that used to be viewed as
inconveniences, as a normal part of the aging process or social issues rather than diseases (Dear
& Webb 2007; Moynihan, 2002, 2010; Moynihan & Cassells 2005; Moynihan, Heath, &
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Henry, 2002; Moynihan & Henry 2006). These include: mild forms of depression and anxiety,
ADHD, social anxiety disorder, intermittent explosive disorder, attention deficit disorder,
irritable bowel syndrome, restless legs, low bone mineral density, hypercholesterolemia,
erectile dysfunction, pre-diabetes, prehypertension, premature ejaculation and female sexual
dysfunction (Brody & Light 2011; Halasz, 2004; Hartley, 2006; Mintzes, 2002; Moynihan,
2003; Tiefer, 2006, 2007; Woloshin & Schwarz 2006).
Critics do not deny the existence of these disorders, the severity of symptoms or the
value of medical treatment for many sufferers. What is argued is that each reflects a problematic
widening of disease definitions that ultimately enables and legitimises medical intervention for
as many people as possible (Alonso-Coello, Garcia-Franco, Guyatt, & Moynihan, 2008; Barbui
& Tansella 2005; Doran & Henry, 2008; Herxheimer, 2003; Medwar, 2001; Verdous &
Cougnard, 2003). Expanding the reach of a condition is problematic where it creates
unwarranted concern (Heath, 2006), unnecessary use of medical services and technologies
(Moynihan & Cassells, 2005), wastes resources on trivial lifestyle conditions or risk factors
(Lexchin, 2001) at the expense of more serious diseases (Freemantle & Hill, 2002; Heath, 2005;
Mintzes, 2006; Moynihan, Heath, & Henry, 2002) unnecessary patient exposure to risk; and
the narrowing of treatment options to saleable products (Moncrieff, Hopker, & Thomas, 2005;
Lexchin, 2006; Tiefer, 2007; Tracey, 2004; Woloshin & Schwarz 2006). The potential to
prompt excessive use of medicines makes disease mongering a significant public health
problem (Buckley, 2004, Moncrieff, Hopker, & Thomas 2005).
Although a relatively new idea in public discussion about pharmaceutical demand and
public health, “disease mongering” has gained considerable currency (Moynihan, Doran, &
Henry, 2008). Disease mongering frequently appears in commentary on pharmaceutical
marketing in the popular news media (commonly “scare-quoted” or italicised) but is
particularly prominent in the medical and public health professional media. Disease mongering
has been the subject of an academic conference and the theme issue of high impact medical
science journal (PLoS Medicine, 2006). The phrase has been discussed in the pages of the New
York Review of Books (Angell, 2004) and has significant internet presence through Wikipedia
and in the commentary of numerous blogs. There is some evidence that disease mongering has
become something more than a handy journalistic trope. The prominence given to disease
mongering in the conclusions of a UK Parliamentary inquiry (House of Commons, 2005)
suggest significant conceptual traction.
To help illustrate the concept of disease mongering and the traction it has gained, we
draw the reader’s attention to an artistic parody of drug promotion (see Figure 1). In 2007, New
York’s Daneyal Mahmood Gallery exhibited “Havidol” a work consisting of faux
advertisements for a fictional prescription drug for an equally fictional condition – Dysphoric
Social Attention Consumption Deficit Anxiety Disorder. The Havidol (have-it-all) parody
generated extensive international public attention for both the artist, Australian Justine Cooper,
and the target of her satire – pharmaceutical promotion and disease mongering. The glossy,
attractive advertisements of the exhibition are notable for not only capturing the slick and
persuasive presentation of drug advertising but for artfully voicing the critique; drug promotion
sells the sickness as well as the (putative) remedies.
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Figure 1 (http://www.havidol.com/ reproduced as ‘fair use’)
The Havidol parody is an artist’s impression of drug promotion and a commentary on
the role of medicines in contemporary social life. However, the art work also shows an element
of the disease mongering critique that is often left implicit in academic writings. While the
Havidol parody, like the wider disease mongering critique, is clearly aimed at drug companies,
the artist made it clear that the parody extends to us all and the “culture of consumerism” and
pursuit of “a life without pain, only gain” (Mahmood, 2007). The caption “When more is not
enough” suggests that the seller is pitching to a grasping public, never satisfied, always wanting
more.
The published disease mongering literature mostly consists of the descriptive reports
and critical commentary on cases of (alleged) disease mongering; cases of aggressive product
promotion and general critiques of pharmaceutical promotion. These reports and commentaries
often make a limited reference to contemporary cultural and political economic conditions and
the kind of people that we have become. In focussing on the marketing activities of drug
companies, claims about consumers and their medicine related behaviours are left indistinct,
although like the Havidol parody, somewhat negative.
As part of a larger study looking at the regulation of pharmaceutical promotion, we
wanted to explore how critics of drug promotion conceptualise consumers and contemporary
medicine use. Rather than rely solely on the published literature, we supplemented our review
by interviewing some of the authors of the disease mongering critique. In this report we use
critics’ extempore description and explanation of disease mongering to develop a theoretically
cogent interpretation of what disease mongering implies or assumes about the contemporary
world, particularly the doctors and consumers who inhabit it, and why such a critique is
considered necessary.
Study Context
Our interest in disease mongering arose from our general research interest in Australia’s
pharmaceutical regulatory arrangements particularly those policies aimed at influencing
consumer behaviour, for example, Australia’s system of universal pharmaceutical insurance
(the Pharmaceutical Benefits Scheme) and its cost sharing requirements. As health social
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scientists our research presupposes that consumer oriented pharmaceutical regulation is
importantly connected to how consumers are believed by regulators to act in regard to
medicines. This reflects a basic sociological premise that our understandings and values give
us all, policy makers as well as consumers, our reasons for action.
In this study we undertook to more closely examine some of the claims that are made
about consumers; in how consumers are presumed to behave, or to put in social scientific terms,
how consumers are constructed as medicine users. Disease mongering, which had become a
prominent element in discussion of Australia’s drug promotion policy, provided our entry point
to exploring the ideas about consumers and their prescription medicine related behaviours.
Ideas such as disease mongering make (or refer to) important empirical, normative and material
claims about the world and how people think and behave. Our investigation starts with scrutiny
of the labelling itself and by talking to the critics who use the phrase, gain a better
understanding of the criticism and its claims.
Methods
An interview study was undertaken with analysis of the data following the techniques
of grounded theory (the version developed by Strauss & Corbin, 1998), such as coding and
constant comparison to identify and relate emergent themes. Our choice of approach was
pragmatic, with grounded theory offering a well-developed interpretive methodology for
systematic qualitative analysis. Our analysis does not represent the fullest expression of
grounded theory; we did not attempt to develop a novel, inductive theory from our data. While
some grounded theory researchers emphasise conclusions being inductively drawn from the
data, it does not exclude developing explanations by articulating insights drawn from new
empirical studies with existing theoretical positions, in this study the theoretical concept of
pharmaceuticalisation.
The project received ethics approval from Human Research Ethics Committee at The
University of Newcastle (approval number H-2008-0071).
We wanted to talk to authors who had published, presented or publicly commented on
pharmaceutical promotion and disease mongering. A list of potential participants was drafted
using existing published literature and current contacts. The literature search involved
searching for the key search term ‘disease mongering’ in Medline, PreMed, Embase, Psycinfo,
CINAHL and Scopus databases. Relevant literature was also found through the reference lists
of relevant books and journal articles. As one prominent and much published commentator on
disease mongering was associated with the research team, this individual was excluded from
participation.
We contacted potential participants via email, providing them with an outline of the
study and an invitation to participate. All of those we contacted agreed to be interviewed. Once
the participant had returned a signed consent form, a time for the interview was arranged. The
consent form indicated that the participant’s personal information would remain confidential
to the researchers.
We interviewed 18 authors, academics and activists (many all three) who had either
written on disease mongering or were recommended to us by someone who had. The
Interviewees were located in the Asia, Australia Canada, Europe, the United States and the
United Kingdom. We ceased recruiting new participants at the point that we believed we had
reached ‘redundancy’ i.e. limited new and relevant information would be likely to emerge from
further interviews.
We conducted the interviews by telephone or via Skype. We digitally recorded all
interviews with the permission of the participants and verbatim transcribed the recordings as
soon as possible after the interview. We used a schedule of general topics (phrased as open-
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ended questions) to be covered in the course of the interview, for example: How would you
define disease mongering? Why does disease mongering happen? How does disease mongering
differ from the ‘legitimate’ raising of disease awareness by the pharmaceutical industry? What
are the consequences of disease mongering? Is disease mongering always effective?
As relevant topics and questions were broached by either the interviewer or the
participant, we asked probing questions to elicit further detail and clarification (Rice & Ezzy,
1999). At the conclusion of each interview, our understanding of the interviewee’s views was
reflected back to the interviewee as a rudimentary check on validity. Interviewees were
encouraged to advise if anything had been misunderstood, misinterpreted or overlooked (Rice
& Ezzy, 1999).
Our analysis of the data involved a process of conceptual categorisation, similar to the
techniques applied by “grounded theory” advocates such as Strauss and Corbin (1998) and
Clarke (2003). The analysis was an interpretive and iterative process of identifying and
grouping (“coding”) concepts that constitute the descriptions and explanations of disease
mongering and associated phenomena. Concepts that are interpreted as significant within and
across texts are analysed, compared and possibly further categorised at a higher level of
abstraction, in this study as themes. Our conceptual categorisation was developed with
reference to a more general interpretative framework “pharmaceuticalisation.”
The steps taken to strengthen the credibility of our analysis followed the guidelines
provided by grounded theorists (Charmaz, 2006; Corbin & Strauss, 2008). We interviewed
informants active in pharmaceutical promotion debates and intimately familiar with the concept
of disease-mongering and the marketing practices it critiques. Our interview guide was wideranging and flexible with interviewees free to move the discussion in any direction they felt
was relevant and interesting. At the conclusion of each interview, our understanding of the
interviewee’s views was described to the interviewee allowing him or her to clarify of correct.
Data coding was undertaken by each of us independently reading and categorising the
interview data, comparing and discussing interpretations and developing a coding scheme. We
then applied the coding scheme independently to all interviews with frequent checks for
consistency. We regularly met to discuss the results the concepts and themes emerging from
our coding and memo-ing. We extensively revisited the interview data to apply new codes and
confirm our developing interpretation. We took care to be reflexive, with our interviewing and
our interpretation of the data being accompanied by us reflecting on and discussing our present
understandings and how these might influence our questions and findings.
The Results section of our report contains numerous segments of data, i.e. quotes from
the interviews, to illustrate concepts and themes and allow the reader to follow, assess and
evaluate our interpretation of interviewee’s descriptions and explanations of disease
mongering.
Results
The results detail some of the common descriptive features of the accounts – how
disease mongering is defined, how interviewees characterised each of the major actors and
contemporary political, economic and cultural circumstances. We first present how
interviewees define disease mongering and then present the three main themes from our
analysis – the potency of pharmaceutical marketing, the hubris of doctors and the susceptibility
of consumers. These themes represent the main axes of interviewee’s explanations for the
problem of disease mongering and why policy and regulation of drug promotion should better
account for it.
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Defining Disease Mongering
There [will always be] death and suffering and there will always be people
offering to alleviate it. Some of it will be good some of it will be nonsense but
most of it will be lucrative.
All of the interviewees described disease mongering as an increasingly prominent
element of the “nonsense” frequently involved in selling medicines. The interviewees claimed
that almost any ‘ill defined’ but measurable physical or mental state presents an opportunity
for a drug manufacturer to start “pushing the boundaries of a diagnosis” or for “creating
diseases or magnifying the importance of diseases.” Depression, anxiety, shyness, attention
deficit disorder, irritable bowel syndrome, restless legs, osteoporosis, erectile dysfunction,
premature ejaculation, female sexual dysfunction, hypertension, pre-menstrual syndrome, high
cholesterol, menopause, insomnia, pre-hypertension, pre-diabetes, over-active bladder,
baldness – were all cited as examples of physical and mental states that had been subjected to
“nonsense” and mongered.
While not denying the suffering that these conditions may entail, the interviewees all
believed that, as one interviewee put it “broad spectrum conditions, ill-defined and easily
confused with day-to-day trials and tribulations of life” are ripe for mongering.
The things that will get mongered…are things that can be measured and where
it can be put to us that our measurements are falling outside some norm, great
pressure can be put on us to try and get ourselves back inside the norm.
Almost anything is measurable on some scale or another. Once measured, what is
“normal” can be defined, and what is otherwise and should concern you can be communicated.
What I see every single day is the widening of the definitions of raised blood
pressure, the cholesterol obsession, bone density obsession, all things that might
harm you in the future but you’re perfectly well now but you’re obsessing about
these things...People spoil the health they have by worrying about [it].
Disease mongering may involve nonsense but to the interviewees it is pernicious
nonsense. The elasticity of “normal” allows for the pathologising of natural human variation.
Interviewees were all concerned that essentially healthy bodies and minds are turned into
problems thereby creating dissatisfaction, worry and unhappiness.
[Disease mongering] is a little bit like the war on terror where you keep the
population worried the whole time…you profoundly change the meaning of
human experience…the natural and spontaneous ways that we go about our
lives are being dissembled by the pharmaceutical industry and all the different
people who can make money out of making us unhappy with bits of our
functioning.
For all interviewees, what disease mongering is most pointedly criticising is that the
sowing of discontent misleads people towards treatments and in doing so needlessly exposes
them to medicines of uncertain benefit and possible harms.

Evan Doran and Clare Hogue

7

Misleading people to the effect that people who were content with their lives
are now unhappy about themselves and motivated to take treatments that will
do them more harm than good.
Another issue of major concern for interviewees was that disease mongering deflects
attention and effort from illness prevention in favour of expensive treatments and diverts
resources from more serious health issues to less serious even trivial matters.
There are opportunity costs at a societal level, it is the focus of time and money
and clinical gaze upon diseases that are mongered then there is a risk that things
that are really causing greater suffering are ignored... If we waste money on
medicines and treatments that are not truly relieving suffering, then that there
are less resources available for other things that are.
For all interviewees, the central problem with disease mongering is that it distorts
understanding and results in treatments reaching beyond those with the capacity to benefit to
those who simply have the capacity to consume.
In many of the interviewees’ accounts, disease mongering was linked closely to
medicalization: “They’re very similar; they each try and make part of the life-world a pathology
or something in need of therapy”; however, as one interviewee remarked disease mongering is
“a particularly pernicious…cynical…extreme and nasty variant of medicalisation.” For some
interviewees, in contrast to disease mongering, medicalisation may also result in a positive
effect. People have benefited as some conditions have come under the medical gaze.
In the past twenty years the medicalisation of chronic pain has been a good
thing, basically for patients and probably doctors as well. The pain
medicine…it’s a case of medicalisation, but I would be very hard to call it
disease mongering.
By comparison, interviewees’ accounts generally suggested the lack of any benefit of
disease mongering for people’s health and wellbeing.
Most of the best selling drugs and medicines don’t treat proper diseases at all…
they are drugs which could be kind of sunk to the bottom of the sea and we
wouldn’t be any the worse off.
Interviewees emphasised that disease mongering is about “creating a need” and that
pharmaceutical companies are as adept at manufacturing need as they are drugs.
Disease mongering and the pharmaceutical industry
Pharmaceutical companies appeared in the interviewees’ descriptions as an entirely
known quantity. The following quotes prosaically state the obvious motive: “it’s an
industry…the main goal is to sell” and “drug companies focus on profit first and foremost.”
“Drug companies are in the business to make money.” The interviewees recognised that the
business of selling drugs is a highly competitive environment where the business edge lies in
innovation but where it is also “much easier to market than to develop drugs.”
[Disease mongering] happens simply because of market pressures…there is a
finite number of sick people out there and pharmaceutical companies are
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functioning in a very competitive market place and need to establish and expand
market share for the products.
Citing factors such as declining productivity of the drug development pipeline,
interviewees described marketing has having come to dominate pharmaceutical enterprise –
with promotion becoming the area of its greatest creativity: “At present what you have is a
great expansion of marketing innovation…a great effervescence of creative invention. I don’t
think that that invention is the kind…that results in better [medicines].”
The focus on marketing and the vast resources devoted to it has seen drug companies
develop into highly capable, subtle and sophisticated marketers willing to aggressively use
whatever means it believes works. For all the interviewees, marketing inventiveness has
increasingly turned to disease mongering. Bringing attention to and informing about a
condition is often akin to “branding” the condition and, somewhat paradoxically, making it
desirable. Changing perceptions of a disease can’t be achieved with pithy slogans and attractive
imagery alone but relies on assuming the language and authority of medical science. As one
interviewee described “It is important for (industry) to create a market…that appears to be valid
and you do that by attaching it to scientific authority or medical authority.” For most
interviewees, the sophistication of drug companies marketing is at its most insidious in this
“pseudo-scientific approach” where the veneer of science is used to persuade people that they
need a remedy.
Interviewees portrayed drug companies as potent, capable and determined. Most of the
accounts told a story of powerful industry following the unambiguous imperative of profit.
Industry appeared as determined in two senses, first, that drug companies are resolute in their
pursuit of profit; and second, that because of ‘market pressures’ they cannot be otherwise. The
very nature of pharmaceutical enterprise determines what industry does “As long as there is a
pharmaceutical industry there will never be no disease mongering.”
All interviewees described drug companies as willing to use whatever means possible
to sell drugs, including deceit. The historical record of egregious, self-serving behaviour by
drug manufacturers (the Vioxx case, for example) was cited by interviewees support the claim.
Few interviewees, however, were excessive in their criticism of pharmaceutical manufacturers
(for example, only one of eighteen interviewees invoked the “snake oil salesman” stereotype).
In the interviewees’ accounts the profit motive means that industry promotion of a drug
and the associated condition will only ever be framed to sell more drugs. The accounts
contained an inventory of strategies and practices – advertising, educating, sponsoring,
lobbying and collaborating, lobbying.
You have to work through opinion leaders and experts; you have to actually get
them to come to the idea themselves. I think you do that by becoming partners
with them and working with them.
The more subtle persuasion mechanisms are the ones in which there is an
attempt to bring everybody on board, to build a consensus over the usefulness
of a given drug…the main mechanism by which that takes place is through a
common moralizing discourse…”Oh you are denying people treatment”.
Pharmaceutical marketing methods weren’t always described as subtle, with some interviewees
expressing the belief that industry succeeds “By buying their way into the professional cabal.”
For one interviewee, pharmaceutical companies “corrupt doctors, they corrupt politicians and
they corrupt the media” in their attempt to define what is normal and what isn’t and should be
treated.
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Doctors and hubris
Doctors appeared in most interviewee’s accounts as well-meaning but too easily
manipulated. While serving the needs of patients should be and mostly is, the primary driver
in their decisions, the desire for effective therapies and a general lack of scientific competency
were cited as making doctors susceptible to the industry’s marketing: “[Doctors] want to have
things that they can help their patients with…they don’t want to hear that the drugs really don’t
work.” and “Doctor’s themselves are brought to the point where they are influenced…most
regular doctors being basically…poor scientists.”
Doctors were described by some interviewees as having been: “completely co-opted by
the pharmaceutical industry” with one interviewee claiming “At the moment Pharma sits like
a shadow in the consultation room.” While doctors were described by some interviewees as
being “entangled” and sometimes “conflicted” through a variety of interactions with drug
companies, the most consistent criticism was of doctors’ overestimation of their capacity to
establish the truth and to manage their relationships with industry: “It is normal for us to believe
that it is only other people who get fooled…that ‘delusion of unique invulnerability’ is the key
risk factor for being misled because when people are over-confident they don’t avoid
exposure.”
In describing doctors and their role in disease mongering most interviewees’ focused
on their limitations. Doctors appeared as vulnerable to being influenced, less because of avarice
or corruption and more because of hubris regarding their capacity to avoid being manipulated.
Interviewees’ expressed concern that doctor’s sense of invulnerability blinds them to the
potential of being misled. The pharmaceutical industry, the ever-present “shadow in the
consultation room” isn’t held by the interviewees to be a benign presence but an insidious coopting force. Marketing claims presented as scientifically sound, a drug company can subdue
a doctor’s scepticism and move them to seeing their patient’s every complaint as treatable.
Consumers and susceptibility
Consumers overwhelmingly appeared in interviewees’ accounts as vulnerable:
“Consumers are pretty much infinitely suggestible.” and “We are very vulnerable to people
who say to us, ‘look, we have a way to help minimise the risks you are at’.” The accounts
suggested that people are “easy prey” to pharmaceutical marketing because they are
preoccupied with but are generally poor evaluators of risk, particularly when it comes to their
health. Interviewees referred to a tendency among people to reach too readily for a medical
diagnosis and “to seek actively the pill for every ill” for what in essence are simply life’s
common travails. As one interviewee explained “Medicine offers us the way to control our
health, our life expectancy, our futures, the futures of our children. The pharmaceutical industry
offers these wonderful therapies, cures, solutions for ills that seem otherwise terrifying.” For
another interviewee, disease mongering works because it “plays on people’s predisposition to
accept that something is a medical problem and needs a medical solution…people seem very
receptive to the idea that they are always suffering.”
Other interviewees identified people’s desire to have their ailments and problems
legitimated, therefore avoiding blame for any perceived shortcoming.
They struggle with issues such as disorganization or forgetfulness or not getting
things finished and so forth …and they think that if they have it defined as
ADHD then it’s not really their fault it is this disorder; disease or dysfunction
that they have and that maybe they can have that repaired by taking some kind
of medication.
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Many interviewees described people as wanting the quick and easy solution rather than
alter their lifestyle: “It’s certainly easier sometimes to take a pill than change the way you are
living your life.” Interviewees also identified people’s strong and limitless desire for
improvement, to be “better than well”.
I don’t think people want to take medication just for the sake of medications…
they think it’s going to improve their life in some kind of way…we’ve seen it
with Prozac. When we see what Peter Kramer calls “people who are looking for
drugs to make them feel better than well.
The desire to be better means people really want to believe their medicines will work
and this can lead them to more readily believe messages about the efficacy of drugs.
By and large people will be concerned about getting an extra year of life. If they
have this even potential promise of reducing their cholesterol which may extend
their life if you or I walked into their home and said, ‘do you realize that the
data in this is being misinterpreted by an industry to malevolently increase the
sales of their drugs?’ I think most people would say ‘Look, yes that’s possibly
true, but I’m in for a gamble here and I don’t want to be in a position of regret
so therefore this is what I’m going to do’.
Many interviewees pointed to how being healthy is now something we value as goal
unto itself and how our health is increasingly an expression of consumerism.
The world we are in now is a world where people say, whoopee, I have ADHD
or bi-polar disorder or I’ve got raised lipids or whatever. People are wearing
their diseases these days almost like a fashion statement.
Most interviewees indicated that consumers can be influenced with industry’s
marketing strategies working through “simple” mechanisms such as saturated media exposure.
It’s a simple practice [to] convince the public…a number [e.g. a prevalence
estimate] is repeated over and over again…people see it in the press, and they
start to believe it, it has to be true because it has been repeated so many times.
People aren’t powerless as consumers or patients; however, an ‘empowered’ patient
can work industry’s way “People themselves they are deciding about their treatments and… in
some cases the consumers can also influence their physicians…to give them sort of drugs that
they need.”
Interviewees’ descriptions of consumers focussed on their vulnerabilities – their
anxieties about risk, their need for and trust in medical explanations, their preference for easy
and quick solutions and their desire for health that can reach for ‘better than well’. It should be
noted that, interviewees didn’t exclude themselves from this vulnerability and acknowledged
that few people are immune to the dread of being sick or the desire to be better. While short of
portraying people as passive dupes, interviewees did portray ‘consumers’ as vulnerable, ever
anxious about their health and always open to new remedies.
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Exposing disease mongering
Revealing the potential for vulnerable people (us all) to be exploited, was the principal
rationale interviewees described as underpinning the disease mongering critique. As one
interviewee explained: “those that realize and that use this term [disease mongering] have a
responsibility to talk about it and to raise awareness in the wider public.” The interviewees
spoke of raising awareness to create skepticism and help people resist the persuasiveness of
drug marketing. Other interviewees described exposing disease mongering as the most
effective way of changing industry behaviour “I do think that there is quite a lot that can be
done to slow [disease mongering]down, to make it harder… is simply by talking about it… by
naming and shaming basically.”
For some of the interviewees, exposure should be supplemented by strengthening
regulation, particularly ensuring that penalties are sufficiently severe.
The appropriate punishment is some kind of costs, and there can be fines or
there can be things like having a government enquiry and calling senior
members of the company to spend a lot of time at enquiries so that they don’t
have time to make money.
Most interviewees identified improving the quality of information to consumers as the
most helpful way to ‘combat’ disease mongering.
We should treat disease mongering as a contaminant information in the media
as we treat micro-organisms in the water, or as we treat pollutants in the
air…[The] health concerns in the nineteenth century (were) to have clean water
for the people…the twentieth century…having clean air for the people, and now
the priority is to have clean information for the people.
I guess the short answer is to get better information to consumers, and helping
the consumers understand that they need to think twice about accepting
diagnosis and any treatment.
Interviewees’ accounts justified the disease mongering critique along the lines of
“muckraking,” the journalistic tradition of exposing the corrupt practices of the powerful.
Disease mongering is the kind of phrase that gets people to take notice and all the interviewees
believed the phrase usefully crystallised their concerns with drug promotion. Interviewee’s
recognised the possible irony in ‘branding’ drug promotion as disease mongering but its
rhetorical force makes the phrase appealing as one means of countering the pervasive messages
of drug marketing.
Discussion
The interviewees descriptions of portray pharmaceutical companies, doctors and
consumers in an unflattering light – industry is venal, doctors are over-confident and consumers
too often credulous. Interviewees tended to emphasise the power and persuasiveness of
industry in contrast to emphasising the vulnerabilities of doctors and consumers. Contemporary
political economic conditions were mostly characterised as favouring pharmaceutical
enterprise with the effectiveness of disease mongering arising from a social cultural milieu
dominated by consumerism, and a preoccupation with being “better than well.” The
interviewees’ main concern was that peoples’ understanding of health and illness is
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increasingly constructed at the confluence of medicine and commerce and that too often our
bodies, minds and moods are measured, normalised and problematised by an imperative to sell
products.
Interviewee’s descriptions and explanations of consumer behaviour did restate the
major issues and themes of the disease mongering literature. That in contemporary society we
are inundated with marketing for any and all consumer goods, creating and targeting our desire
for more and more (De Graaf, Wann, & Naylor, 2005). Marketing focuses our attention on
what we lack, rather than what we have and conditions us to address any imperfections with
consumption (Applbaum, 2006). The rise of the commodification of health care has led medical
treatments to become more like common goods and subject to market forces encouraging us to
recast our self-perception from passive patient to active consumer (Conrad, 2005). While the
transformation of patient to consumer can be empowering Conrad 2005) and a moral gain
(Moynihan & Smith, 2002) it can also have concrete adverse health effects. Healthy people
consider themselves sick, take drugs they don’t need, experience side effects and pay the costs
for the medication without any benefit (Alonos-Coello et al., 2008; Caplan & Elliot, 2004; Dear
& Webb, 2007; Gonzalez, 2010; Woloshin & Schwarz, 2006;). While a diagnosis may benefit
those who are genuinely sick, the creation of “patients” who are not actually sick may create
anxiety and side effects from treatment, thereby creating genuine illness outweighing any
prospective value (Caplan & Elliot, 2004; Woloshin & Schwarz, 2006).
The accounts of interviewees reflect the concern with what Clarke et al. (2003) refer to
as the era of “biomedicalisation.” An extension of the more familiar concept of medicalisation,
biomedicalisation is a term “for the increasingly complex, multisited, multidirectional
processes of medicalisation that today are being both extended and reconstituted through the
emergent social forms and practices of a highly and increasingly techno-scientific
biomedicine” (Clarke et al., 2003) Where medicalisation extends medical jurisdiction over
aspects of life not previously as illnesses, the process of biomedicalisation extends and
commodifies this jurisdiction further over health itself (Clarke et al., 2003). Biomedicalisation
emerges from a political economic and cultural environment characterised by a fusion of public
and private interests, heightened sensitivity to risk and health, continuous in advances medical
and information science and technologies and increased potential to transform bodies and
identities (Clarke et al., 2003).
In a biomedicalised world, the management of not only illness but of “health” too rests
with the individual, a responsibility loaded with a moral imperative to be ever better. To
maintain an optimal healthy state an individual has to manage and assess their risks through
continuous self-surveillance. Concurrently, the proliferation of more sophisticated biomedical
assessment technologies has altered our perception of what it is to be normal and what risks we
face. Technoscientific advances in biomedicine have “molecularised” and “geneticised” our
bodies, expanding the range of what can be measured and worked on (Clarke et al., 2003). We
are all always notionally “at risk” not just of illness and of not being normal but of not being
better than we are.
Pharmaceuticalisation
The interviewees’ accounts can also be seen in the light of a more recent sociological
concept “pharmaceuticalisation” that more directly focuses on the social processes
transforming ever more aspects of the life world into the prospects for pharmaceutical treatment
(Fox & Ward, 2008, Williams Martin, & Gabe, 2011). The pharmaceuticalisation thesis asserts
that pharmaceuticals (including over-the-counter products as well as prescription) have become
part of our daily lives linking “the economics and politics of pharmaceutical production to the
private lives of citizens” (Fox & Ward, 2008) Seen as an occasionally positive, but mostly
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negative, consumer preference and choice for pharmaceuticals, pharmaceuticalisation
highlights the increasing fusion of “the economics and politics of pharmaceutical production
to the private lives of citizens” (Fox & Ward, 2008).
The pharmaceuticalisation thesis shares many of the concepts and concerns of disease
mongering, medicalisation and biomedicalisation. Pharmaceuticalisation, like the disease
mongering critique, gives the pharmaceutical industry a primary role in the expansion in range
and use of pharmaceutical products. Pharmaceuticalisation theorists recognise that drug
promotion (including disease mongering) is important in how pharmaceuticals have come to
be such a pervasive aspect of health behaviour, but argue that disease mongering does not
adequately account for the broader social and political-economic factors at play. Williams et
al. (2011) contend that: “While disease mongering thus captures an important range of issues
pertinent to the broader concept of pharmaceuticalisation, its analytic value is clearly restricted.
Pharmaceuticalisation on the other hand, may or may not involve elements of disease
mongering on the part of the pharmaceutical industry, though often this is not the case”
(Williams et al., 2011).
The pharmaceuticalisation thesis, like biomedicalisation, places medicine and medical
science as central to the expansion of what bodily conditions are to be regarded as candidates
for treatment which pushes drug innovation into evermore areas of health; and beyond health
into “enhancement” and into peoples “health futures” through the development of
pharmacogenomics and pharmacogenetics (Abraham, 2010; Williams et al., 2011). A major
difference between medicalisation and pharmaceuticalisation according to Abraham (2010), is
that pharmaceuticalisation “can grow without expansion of medicalisation, because some drugs
are increasingly used to treat an established medical condition involving no transformation of
a non-medical problem into a medical one” (Abraham 2010).
Pharmaceuticalisation theory includes disease mongering and biomedicalisation but
places these among a number of other key explanatory factors such as consumerism, the media
and the ideology of the regulatory state that are “mutually interactive but competing in creating
consumer demand for pharmaceuticals” (Abraham, 2010).
Pharmaceuticalisation theory gives a central role to the neo-liberalist ideas dominating
the regulation and governance of pharmaceuticals, particularly the increasingly close
relationship between regulators and manufactures that has resulted in a lowering of regulatory
hurdles to allow manufacturers to “fast track” their patented medicines to the market often
before they have been adequately proven as either safe or effective (Abraham, 2010a; Williams
et al., 2011)
Williams et al, (2011) emphasise the contribution of the popular media to
pharmaceuticalisation. Mediating the “(re)framing of health problems in the media and popular
culture as having a pharmaceutical solution” (2011, page no.) lends a degree of validity to
consumers regarding conditions and pharmaceutical treatments. While the media can tell
negative stories about pharmaceuticals, there is a tendency for news reports to be ‘celebratory’
where pharmaceuticals are “treated as magic bullets for a range of day to day life problems”
(Williams, Martin, & Gabe, 2011). Williams et al. view of “mediation” diverges slightly from
the disease mongering critique in which the media are “co-opted,” seeing the media less as a
catalyst and more as an amplifier of “selling sickness” (Williams, Martin, & Gabe, 2011).
Although not a “puppet of pharmaceutical interests” (Williams, Martin, & Gabe, 2011) the
media’s portrayal of pharmaceuticals may ultimately serve those interests by encouraging
medicalisation and pharmaceuticalisation.
Pharmaceuticalisation theorists point to rising consumerism characterised by greater
reflexivity, expertise and activism among patients. Pharmaceuticalisation involves the choices
of the consumers who may regard themselves as “experts” and “information rich” and able to
evaluate advertising claims about prescription drugs (Abraham, 2010b). This process
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transforms needy patients to demanding patients. Abraham argues that the construction of
patients as ‘experts amounts to the “ideological appropriation of patients’ needs as consumer
demands” (Abraham, 2010a). This “expert patient discourse” largely serves the interests of
drug manufacturers seeking to relax the bans on DTCA imposed by most nations. Williams
and colleagues point out that the discourse of the ‘expert patient’ is not solely the “ideological
appropriation” of consumers by the pharmaceutical industry but is also a feature of government
policies encouraging consumers to be engaged in their health and treatment choices (Williams,
Martin, & Gabe, 2011).
Another version of the pharmaceuticalisation thesis is offered by Fox and Ward (2008)
who identify two major processes: the domestication of pharmaceutical consumption so that it
becomes a part of daily routines and “life-style” marketing of drugs, both of which produce a
situation where “pharmaceuticals come to be seen by consumers as a ‘magic bullet’ to resolve
problems of daily life” (Fox & Ward, 2008) (almost identical wording to Williams et al., 2011).
Fox and Ward focus on the opportunities that the internet generally, and the advent of outlets
such as on-line pharmacies have created to bring pharmaceuticals directly into peoples’ homes
(Fox & Ward, 2008).
With the easy reach of the internet, a consumer can readily access information on the
condition and the drugs, and further, can bypass their doctor and obtain these drugs via online
suppliers. The internet has transformed people from being passive recipients of medical care
to being active consumers, to the point where, consumers are now “a key element in the
pharmaceutical ‘distribution chain’, alongside physicians, academic opinion leaders, patient
advocacy groups, public health bodies and ethicists” (Fox & Ward, 2008).
Although the various social processes are conceived of slightly differently,
pharmaceuticalisation theorists converge on seeing the demand for medicine as created by
social forces that include, but are not confined to, the activities of drug manufacturers. Drug
promotion and disease mongering occur within a social context where public health authorities
encourage people to be aware of their health and actively engaged in minimising risks. There
is also a prevalent consumerist ethos that pushes people towards enhancing themselves through
the consumption of (putative) dug innovations.
Recognition of broader social forces beyond drug promotion and disease mongering
does not stop pharmaceuticalisation theorists from pointing their finger at drug manufacturers.
Although Williams et al. (2011) maintain pharmaceuticalisation is a value neutral concept, it
is clearly couched in strongly normative terms such as “colonisation” – a concept more
generally seen to indicate exploitation of those being colonised, in this case consumers.
However, in pharmaceuticalisation, drug marketing is only factor in the pharmaceutical
“colonisation of the life-world” (Williams et al., 2011) where our everyday health related
behaviours “from the bedroom to the kitchen” (Fox & Ward, 2008) and even our imagination
(Williams, Martin, & Gabe, 2011) is caught by the promise of pharmaceuticals.
All of the pharmaceuticalisation theorists challenge the idea of the “expert patient.”
While consumers are acknowledged to have greater access to information, particularly through
using the internet, there is concern this simply incites demand without necessarily increasing
sound knowledge and expectations of pharmaceuticals. The quality of information available to
them (much of it produced by or influenced by drug manufacturers) may mean that these
demanding consumers may not become as “expert” as they may think. While consumers may
be more informed about medicines than in the past, their better knowledge gives them only a
weak capacity to act as a countervailing force against the broader processes of
pharmaceuticalisation (Busfield, 2010).
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Limitations
Relatively short, one-off interviews are unlikely to elicit and catch the speaker’s final
word on the many aspects of the situation and the analysis does not exhaust interpretive
possibility. While interviewees offered similar descriptions and explanations of disease
mongering as a social process it is not suggested that they would agree on all relevant aspects
of the wider situation. If the analysis emphasises interviewee’s more negative views of the
industry, doctors and consumers involved are presented, it is acknowledged that there was little
in our questioning strategy to prompt positive views. That stated, our interviews did allow
interviewees the opportunity to talk about any aspect they felt was relevant to disease
mongering and pharmaceutical promotion more generally.
Conclusion
Disease mongering involves an implicit critical commentary on contemporary social
life but this does not dissipate the force of its censure of pharmaceutical marketing. For the
interviewees, one of the main objections to disease mongering is the restless dissatisfaction
with ourselves that it plays on and exacerbates. Pharmaceuticalisation argues that this
dissatisfaction emerges from, and reinforces, the more diffuse social processes of
biomedicalisation and pharmaceuticalisation. Pharmaceutical marketing practices such as
disease mongering (mis)shape understanding about what is normal and healthy but this also
results from the focus on individual responsibility for managing health and risk promulgated
by public health officials. The troubling net consequence is too much medicine. Opportunities
both to the community and to the individual are lost by diverting attention to often less serious
conditions while important conditions are neglected. This costs us materially but it also costs
us subjectively, we can end up imagining our health futures to be reliant on pharmaceuticals.
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